治疗药物监测、液体活检或药物基因组学预测药物代谢与反应
本文综述了药物基因组学、治疗药物监测(TDM)和基于液体活检的肝脏ADME基因表达监测三种策略在预测个体间药物代谢与反应差异方面的优势与局限。作者指出液体活检的临床应用仍需更大规模队列验证,现代质谱仪提升了传统TDM的性能,而未来药物基因组学应着重识别缺失的遗传因素,并需结合长读长NGS与表型研究及AI分析系统。
要点
- 液体活检评估肝脏ADME基因表达预测药物代谢的效用尚需更大规模队列研究验证。
- 现代质谱仪使传统TDM更通用、更灵敏,内源性或膳食标志物可简化CYP代谢表型判定。
- 未来药物基因组学应利用大规模、特征明确的患者研究识别缺失的遗传因素并控制混杂因素。
核心结论
- 药物基因组学、TDM和液体活检是应对药物代谢与反应个体间差异的三种关键策略,各有优势与局限。
- 液体活检预测药物代谢的临床效用尚需更大规模队列研究验证。
- 未来需整合长读长NGS全基因组数据与患者表型数据并纳入AI分析系统以预测药物代谢和反应。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 现代质谱仪改善了传统TDM方法,提供通用性和灵敏度。
- 识别CYP代谢特征的内源性或膳食标志物可提供比表型测定更简单、更经济有效的替代方案。
关键数值与推荐
- 未来药物基因组学临床应用应优先识别缺失的遗传因素,采用更大规模、特征明确的患者研究并控制饮食、合并用药和身体健康等混杂因素。
- 需开展结合全基因组长读长NGS与服用不同药物患者表型的大规模研究以识别缺失的遗传力。
临床怎么用
- 临床可借助现代质谱TDM和内源性或膳食标志物评估CYP代谢表型。
- 液体活检肝脏ADME基因表达预测药物代谢尚未常规用于临床,需等待更大规模验证。
局限性
- 液体活检基于肝脏ADME基因表达评估预测药物代谢的效用尚未经大规模队列验证。
- ADME基因表达调控复杂,缺失的遗传因素尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacokinetics plays a central role in understanding the significant interindividual differences that exist in drug metabolism and response. Effectively addressing these differences requires a multi-faceted approach that encompasses a variety of tools and methods. In this review, we examine three key strategies to achieve this goal, namely pharmacogenomics, therapeutic drug monitoring (TDM) and liquid biopsy-based monitoring of hepatic ADME gene expression and highlight their advantages and limitations. We note that larger cohort studies are needed to validate the utility of liquid biopsy-based assessment of hepatic ADME gene expression, which includes prediction of drug metabolism in the clinical setting. Modern mass spectrometers have improved traditional TDM methods, offering versatility and sensitivity. In addition, the identification of endogenous or dietary markers for CYP metabolic traits offers simpler and more cost-effective alternatives to determine the phenotype. We believe that future pharmacogenomic applications in clinical practice should prioritize the identification of missing heritable factors, using larger, well-characterized patient studies and controlling for confounding factors such as diet, concomitant medication and physical health. The intricate regulation of ADME gene expression implies that large-scale studies combining long-read next-generation sequencing (NGS) of complete genomes with phenotyping of patients taking different medications are essential to identify these missing heritabilities. The continuous integration of such data into AI-driven analytical systems could provide a comprehensive and useful framework. This could lead to the development of highly effective algorithms to improve genetics-based precision treatment by predicting drug metabolism and response, significantly improving clinical outcomes.
引用
- Ingelman-Sundberg M, Molden E. Therapeutic drug monitoring, liquid biopsies or pharmacogenomics for prediction of human drug metabolism and response. Br J Clin Pharmacol. 2024. PMID: 38523083. doi:10.1111/bcp.16048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。